United Therapeutics Corporation Sales Revenue, Goods, Net (Deprecated 2018-01-31)
United Therapeutics Corporation (UTHR) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $1.73 billion for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-02-21
- United Therapeutics Corporation sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $464.70M, a 13.62% increase year-over-year.
- United Therapeutics Corporation sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $445.50M, a 9.14% increase year-over-year.
- United Therapeutics Corporation sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $444.60M, a 7.76% increase year-over-year.
- United Therapeutics Corporation sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $370.50M, a 0.41% increase year-over-year.
- United Therapeutics Corporation sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $1.73B, a 7.91% increase from fiscal 2016.
- United Therapeutics Corporation sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $1.60B, a 9.46% increase from fiscal 2015.
- United Therapeutics Corporation sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $1.46B, a 14.15% increase from fiscal 2014.
- United Therapeutics Corporation sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $1.28B, a 15.59% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | $464.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $910.20M derived: sum of 2 quarters · filed 2018-02-21 | $1.35B derived: sum of 3 quarters · filed 2018-02-21 | $1.73B 10-K · filed 2018-02-21 | ||||
| 2017-09-30 | $445.50M 10-Q · filed 2017-10-25 | $890.10M derived: sum of 2 quarters · filed 2017-10-25 | $1.26B 10-Q · filed 2017-10-25 | $1.67B derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2017-06-30 | $444.60M 10-Q · filed 2017-07-27 | $815.10M 10-Q · filed 2017-07-27 | $1.22B derived: sum of 3 quarters · filed 2018-02-21 | $1.63B derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2017-03-31 | $370.50M 10-Q · filed 2017-04-26 | $779.50M derived: sum of 2 quarters · filed 2018-02-21 | $1.19B derived: sum of 3 quarters · filed 2018-02-21 | $1.60B derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-12-31 | $409.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $817.20M derived: sum of 2 quarters · filed 2018-02-21 | $1.23B derived: sum of 3 quarters · filed 2018-02-21 | $1.60B 10-K · filed 2018-02-21 | ||||
| 2016-09-30 | $408.20M 10-Q · filed 2017-10-25 | $820.80M derived: sum of 2 quarters · filed 2017-10-25 | $1.19B 10-Q · filed 2017-10-25 | $1.59B derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-06-30 | $412.60M 10-Q · filed 2017-07-27 | $781.60M 10-Q · filed 2017-07-27 | $1.19B derived: sum of 3 quarters · filed 2018-02-21 | $1.57B derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-03-31 | $369.00M 10-Q · filed 2017-04-26 | $773.20M derived: sum of 2 quarters · filed 2018-02-21 | $1.16B derived: sum of 3 quarters · filed 2018-02-21 | $1.50B derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2015-12-31 | $404.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $788.90M derived: sum of 2 quarters · filed 2018-02-21 | $1.13B derived: sum of 3 quarters · filed 2018-02-21 | $1.46B 10-K · filed 2018-02-21 | $1.46B 10-K · filed 2016-02-25 | |||
| 2015-09-30 | $384.70M 10-Q · filed 2016-10-27 | $384.71M 10-Q · filed 2015-10-27 | $730.50M derived: sum of 2 quarters · filed 2016-10-27 | $1.06B 10-Q · filed 2016-10-27 | $1.06B 10-Q · filed 2015-10-27 | $1.40B derived: sum of 4 quarters · filed 2017-02-22 | ||
| 2015-06-30 | $345.80M 10-Q · filed 2016-07-28 | $345.75M 10-Q · filed 2015-07-28 | $671.70M 10-Q · filed 2016-07-28 | $671.67M 10-Q · filed 2015-07-28 | $1.02B derived: sum of 3 quarters · filed 2017-02-22 | $1.35B derived: sum of 4 quarters · filed 2017-02-22 | ||
| 2015-03-31 | $325.90M 10-Q · filed 2016-04-28 | $325.92M 10-Q · filed 2015-04-28 | $671.25M derived: sum of 2 quarters · filed 2017-02-22 | $999.52M derived: sum of 3 quarters · filed 2017-02-22 | $1.32B derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2014-12-31 | $345.35M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $673.62M derived: sum of 2 quarters · filed 2017-02-22 | $994.95M derived: sum of 3 quarters · filed 2017-02-22 | $1.28B 10-K · filed 2017-02-22 | $1.28B 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $328.27M 10-Q · filed 2015-10-27 | $649.60M derived: sum of 2 quarters · filed 2015-10-27 | $934.15M 10-Q · filed 2015-10-27 | $1.22B derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $321.33M 10-Q · filed 2015-07-28 | $605.88M 10-Q · filed 2015-07-28 | $892.18M derived: sum of 3 quarters · filed 2016-02-25 | $1.19B derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $284.55M 10-Q · filed 2015-04-28 | $570.85M derived: sum of 2 quarters · filed 2016-02-25 | $870.86M derived: sum of 3 quarters · filed 2016-02-25 | $1.15B derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $286.30M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $586.30M derived: sum of 2 quarters · filed 2016-02-25 | $863.80M derived: sum of 3 quarters · filed 2016-02-25 | $1.11B 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | $300.01M 10-Q · filed 2014-10-28 | $577.50M derived: sum of 2 quarters · filed 2014-10-28 | $820.65M 10-Q · filed 2014-10-28 | $1.06B derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $277.50M 10-Q · filed 2014-07-29 | $520.64M 10-Q · filed 2014-07-29 | $761.07M derived: sum of 3 quarters · filed 2015-02-24 | $1.00B derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $243.15M 10-Q · filed 2014-04-29 | $483.58M derived: sum of 2 quarters · filed 2015-02-24 | $724.49M derived: sum of 3 quarters · filed 2015-02-24 | $946.33M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2012-12-31 | $240.43M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $481.35M derived: sum of 2 quarters · filed 2015-02-24 | $703.18M derived: sum of 3 quarters · filed 2015-02-24 | $906.12M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $240.92M 10-Q · filed 2013-10-29 | $462.75M derived: sum of 2 quarters · filed 2013-10-29 | $665.69M 10-Q · filed 2013-10-29 | $860.00M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $221.83M 10-Q · filed 2013-07-25 | $424.77M 10-Q · filed 2013-07-25 | $619.09M derived: sum of 3 quarters · filed 2014-02-25 | $820.11M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $202.94M 10-Q · filed 2013-04-25 | $397.25M derived: sum of 2 quarters · filed 2014-02-25 | $598.27M derived: sum of 3 quarters · filed 2014-02-25 | $781.82M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $194.31M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $395.33M derived: sum of 2 quarters · filed 2014-02-25 | $578.88M derived: sum of 3 quarters · filed 2014-02-25 | $741.09M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $201.02M 10-Q · filed 2012-11-01 | $384.57M derived: sum of 2 quarters · filed 2012-11-01 | $546.78M 10-Q · filed 2012-11-01 | $710.18M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $183.55M 10-Q · filed 2012-07-26 | $345.76M 10-Q · filed 2012-07-26 | $509.16M derived: sum of 3 quarters · filed 2013-02-26 | $677.40M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $162.22M 10-Q · filed 2012-04-26 | $162.24M 10-Q · filed 2011-04-28 | $325.61M derived: sum of 2 quarters · filed 2013-02-26 | $493.85M derived: sum of 3 quarters · filed 2013-02-26 | $628.29M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2010-12-31 | $163.40M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $331.63M derived: sum of 2 quarters · filed 2013-02-26 | $466.07M derived: sum of 3 quarters · filed 2013-02-26 | $591.70M 10-K · filed 2013-02-26 | $591.88M 10-K · filed 2011-02-24 | |||
| 2010-09-30 | $168.24M 10-Q · filed 2011-10-27 | $168.30M 10-Q · filed 2010-10-28 | $302.68M derived: sum of 2 quarters · filed 2011-10-27 | $428.31M 10-Q · filed 2011-10-27 | $428.44M 10-Q · filed 2010-10-28 | $534.06M derived: sum of 4 quarters · filed 2012-02-28 | ||
| 2010-06-30 | $134.44M 10-Q · filed 2011-07-28 | $134.46M 10-Q · filed 2010-07-28 | $260.07M 10-Q · filed 2011-07-28 | $260.13M 10-Q · filed 2010-07-28 | $365.82M derived: sum of 3 quarters · filed 2012-02-28 | $459.88M derived: sum of 4 quarters · filed 2012-02-28 | ||
| 2010-03-31 | $125.67M 10-Q · filed 2011-04-28 | $231.39M derived: sum of 2 quarters · filed 2012-02-28 | $325.44M derived: sum of 3 quarters · filed 2012-02-28 | $406.45M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2009-12-31 | $105.71M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $199.77M derived: sum of 2 quarters · filed 2012-02-28 | $280.78M derived: sum of 3 quarters · filed 2012-02-28 | $357.64M 10-K · filed 2012-02-28 | $357.87M 10-K · filed 2011-02-24 | |||
| 2009-09-30 | $94.06M 10-Q · filed 2010-10-28 | $175.07M derived: sum of 2 quarters · filed 2010-10-28 | $251.93M 10-Q · filed 2010-10-28 | |||||
| 2009-06-30 | $81.01M 10-Q · filed 2010-07-28 | $157.87M 10-Q · filed 2010-07-28 | ||||||
| 2008-12-31 | $270.00M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |